PRESCRIPTION OF FIRST-LINE EMPIRICAL TREATMENTS FOR HELICOBACTER PYLORI INFECTION OUTSIDE EUROPE: RESULTS OF 15,000 CASES FROM THE WORLD-WIDE REGISTRY ON H. PYLORI MANAGEMENT (WORLDHPREG) (UEGW 2026) - Jul 15, 2026 - Abstract #PP0506; Pres time: Oct 18, 2026; 09:00 AM - 06:00 PM; Location: Hall 7 Poster Area; "Other regimens included triple therapy with PPI-amoxicillin-levofloxacin (9.1%) and dual therapy with PPI-amoxicillin (8.1%). The WorldHpReg demonstrates marked regional heterogeneity in first-line H. pylori therapies, with predominance of standard triple therapy with PPI-amoxicillin-clarithromycin and limited use of quadruple regimens, highlighting the need for local treatment protocols to improve eradication rates."
Clinical • Dyspepsia • Gastroenterology • Infectious Disease
|
|
P. Parra 1; L. Moreira Ruiz 2; A.J. Riquelme Pérez 3; D. Reyes-Placencia 4; L. Coelho 5; M. Alboraie 6; S. Prasad Singh 7; R.-K. Vilaichone 8; S.I. Smith 9; S.C. Shah 10; L. Kamani 11; F. Alsohaibani 12; S. Veldhuyzen Van Zanten 13; M. Akroush 14; S. Inns 15; P. Katelaris 16; I. A. Naqid 17; G. Boldbaatar 18; J.M. Remes-Troche 19; P. Bongkotvirawan 20; O. Laudanno 21; V. G. Mohan Prasad 22; W. Otero 23; M. Kumar Sahu 24; S.R. Chaves 25; L. Soares da Silva 26; J.C. Soares Veloso 27; O. Varas 28; R. Castaño-Llano 29; J. Ramirez 30; H. Okamoto 31; C. von Muhlenbrock 32; R. Vicente De Paula 33; J. Marinho 34; E. Comelli 35; D. Cabrera Hinojosa 36; V. Kayamba 37; C. Campos Nuñez 38; G. Otoya 39; G. Coutinho Couto 40; H. Breyer 41; C. Alencar 42; H. Cedron 43; S. Portillo 44; S. Nistala 45; A. Lee 10; L. Huidobro 46; I. Hanna-Jairala 47; O.P. Nyssen 1; J.P. Gisbert 1; on behalf of the World-HpReg investigators; Pablo Parra; Leticia Moreira Ruiz; both first authors; contributed equally to the study; Olga P. Nyssen; Javier P. Gisbert; both senior authors; contributed equally to the study
|